Genus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENUS, and what generic alternatives to GENUS drugs are available?
GENUS has twenty-five approved drugs.
There are seven US patents protecting GENUS drugs.
There are forty-five patent family members on GENUS drugs in twenty-one countries and fifteen supplementary protection certificates in six countries.
Summary for Genus
| International Patents: | 45 |
| US Patents: | 7 |
| Tradenames: | 19 |
| Ingredients: | 19 |
| NDAs: | 25 |
Drugs and US Patents for Genus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus | CARBINOXAMINE MALEATE | carbinoxamine maleate | SOLUTION;ORAL | 040458-001 | Apr 25, 2003 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Genus Lifesciences | OXYCODONE HYDROCHLORIDE | oxycodone hydrochloride | CAPSULE;ORAL | 200534-001 | Oct 20, 2010 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | DISCN | Yes | No | 9,539,214 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-010 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,231,931 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-009 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,231,931 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Genus | DIPYRIDAMOLE | dipyridamole | TABLET;ORAL | 040898-001 | Apr 23, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Genus | TIVORBEX | indomethacin | CAPSULE;ORAL | 204768-002 | Feb 24, 2014 | DISCN | Yes | No | 8,734,847 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | 9,364,439 | ⤷ Try a Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | 6,926,907 | ⤷ Try a Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | 9,364,439 | ⤷ Try a Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | 6,926,907 | ⤷ Try a Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | 8,206,741 | ⤷ Try a Trial |
| Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | 8,206,741 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 81 mg/40 mg | ➤ Subscribe | 2016-10-14 |
International Patents for Genus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2759125 | ⤷ Try a Trial |
| South Korea | 20150030782 | ⤷ Try a Trial |
| European Patent Office | 2797600 | ⤷ Try a Trial |
| Singapore | 175315 | ⤷ Try a Trial |
| Israel | 215872 | ⤷ Try a Trial |
| Australia | 2016200397 | ⤷ Try a Trial |
| European Patent Office | 2421513 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1718641 | 2012/008 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 0809498 | 10C0038 | France | ⤷ Try a Trial | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 1499331 | 13C0055 | France | ⤷ Try a Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| 0480717 | 98C0025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
| 1441735 | 2008/010 | Ireland | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220; |
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
